ANIK revenue and margins rise, but Hyalofast U.S. PMA setback clouds outlook
ANIK third-quarter revenue grew 10% year on year and gross margin rose 6 points. Hyalofast's U.S. PMA was deemed not approvable, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to a TradingView summary, Anika Therapeutics posted third-quarter revenue growth of 10% year on year, while its gross margin expanded by 6 percentage points. Adjusted EBITDA for the first nine months reached $16.5 million.
At the same time, the U.S. PMA application for Hyalofast was deemed not approvable. A Cingal NDA submission is targeted for 2027.
why it matters
For investors the picture is mixed: stronger revenue and margins support the company's financials, but the Hyalofast PMA setback delays part of the commercial path, and the Cingal filing is not expected until 2027.
market impact
ANIK: stronger revenue and margins offset by the Hyalofast PMA setback, mixed pressure
- ANIK mixed — revenue and margin gains conflict with the Hyalofast application setback
tags
instruments
sources
- ANIK: Revenue and margins improved; Hyalofast's U.S. PMA setback and Cingal's 2027 NDA target shape the outlook — TradingView, 6 November 2026 at 19:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗